Sotera Health (SHC) News
Filter SHC News Items
SHC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SHC News Highlights
- For SHC, its 30 day story count is now at 6.
- Over the past 4 days, the trend for SHC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about SHC are COOK and SON.
Latest SHC News From Around the Web
Below are the latest news stories about SOTERA HEALTH CO that investors may wish to consider to help them evaluate SHC as an investment opportunity.
Needham Downgrades This Medical Equipment Stock Due To Lawsuit RiskA Cook County jury awarded $363 million to a woman who developed breast cancer after living close to a medical device sterilization facility run by Sterigenics, a unit of Sotera Health Co (NASDAQ: SHC). The lawsuit was related to ethylene oxide (EO) exposure, a disinfectant used to sterilize medical devices. The trial was the first of many to come against the Willowbrook plant operators, with more than 760 lawsuits against it in Cook County Circuit Court for toxic emissions. Needham expects conc |
Why Sotera Health Got Slammed Again on WednesdayThe hits keep coming for Sotera Health (NASDAQ: SHC), the beleaguered company that just suffered a stinging legal defeat. This was due to yet another analyst lowering his recommendation on the shares. JPMorgan Chase prognosticator Tycho Peterson weighed in with a new take on Sotera stock before market hours. |
10 Biggest Losers TodayIn this article, we will take a look at the 10 biggest losers today. If you want to see some other stocks losing value on Wednesday, go directly to 5 Biggest Losers Today. Wall Street’s key indices opened marginally higher this morning. However, they turned red in mid-day trading Wednesday after the Federal Reserve lifted […] |
Why Sotera Health Stock Tumbled Again on TuesdayFor the second straight day, beleaguered Sotera Health (NASDAQ: SHC) took a wallop on the stock exchange Tuesday. Tuesday morning, Goldman Sachs analyst Amit Hazan lowered his Sotera recommendation to neutral from the previous buy. A clutch of plaintiffs have filed similar lawsuits against Sotera and its peers, alleging that one of those companies -- Sotera subsidiary Sterigenics -- produced highly carcinogenic emissions from its factory near Chicago. |
Here’s Why Sotera Health Plunged Almost 30%Shares of Sotera Health (NASDAQ:SHC) cratered on Monday by almost 30% after a jury awarded $363 million in a lawsuit. A woman had sued the company's Sterigenics unit claiming that she had developed breast cancer as a result of its plant's emissions. However, it's possible that the final award might be smaller in the range of $150 million to $200 million, according to Barclays. |
Why Sotera Health Stock Crumbled TodayAs a result, Sotera's stock price plummeted by more than 33% on the day. Kamuda claimed that ethylene oxide emissions from a Sterigenics factory in the state caused her breast cancer and the non-Hodgkin's lymphona suffered by her son. |
Sotera Health Company's (NASDAQ:SHC) Intrinsic Value Is Potentially 89% Above Its Share PriceHow far off is Sotera Health Company ( NASDAQ:SHC ) from its intrinsic value? Using the most recent financial data... |
Sotera Health Company (SHC) Q2 2022 Earnings Call TranscriptAt this time, I would like to welcome everyone to the Sotera Health second quarter 2022 earnings call. This webcast is being recorded, and a replay will be available in the Investor Relations section of the Sotera Health website. On the call with me today are Michael Petras, chairman and chief executive officer; and Michael Biehl, interim chief financial officer. |
Sotera Health Company (SHC) Tops Q2 Earnings and Revenue EstimatesSotera Health Company (SHC) delivered earnings and revenue surprises of 12.50% and 3.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock? |
Sotera Health Reports Second-Quarter and First-Half 2022 ResultsQ2 2022 net revenues of $267 million increased 6%, compared to Q2 2021Q2 2022 net income of $30 million or $0.11 per diluted share, compared to net income of $43 million or $0.15 per diluted share in Q2 2021Q2 2022 Adjusted EBITDA of $136 million increased 1%, compared to Q2 2021Q2 2022 Adjusted EPS of $0.27 increased $0.01, compared to Q2 2021 Narrowing full-year 2022 net revenues and Adjusted EBITDA outlook in the range of $1.0 to $1.022 billion and $515 to $525 million, respectively CLEVELAND |